- Previous Close
93.57 - Open
94.00 - Bid 92.47 x 200
- Ask 93.13 x 200
- Day's Range
91.47 - 94.33 - 52 Week Range
33.45 - 103.81 - Volume
433,576 - Avg. Volume
839,148 - Market Cap (intraday)
5.016B - Beta (5Y Monthly) 1.00
- PE Ratio (TTM)
-- - EPS (TTM)
-1.95 - Earnings Date Oct 28, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
101.00
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
www.procept-biorobotics.comRecent News: PRCT
View More
Performance Overview: PRCT
Trailing total returns as of 11/20/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PRCT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PRCT
View MoreValuation Measures
Market Cap
5.02B
Enterprise Value
4.90B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
23.81
Price/Book (mrq)
20.79
Enterprise Value/Revenue
24.52
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-50.07%
Return on Assets (ttm)
-16.73%
Return on Equity (ttm)
-37.02%
Revenue (ttm)
199.84M
Net Income Avi to Common (ttm)
-100.06M
Diluted EPS (ttm)
-1.95
Balance Sheet and Cash Flow
Total Cash (mrq)
196.76M
Total Debt/Equity (mrq)
34.26%
Levered Free Cash Flow (ttm)
-82.85M
Research Analysis: PRCT
View MoreCompany Insights: PRCT
PRCT does not have Company Insights